Evercore ISI keeps Fortrea at Outperform and lifts price target to $28
Evercore ISI maintained its Outperform rating on Fortrea Holdings and raised its price target from $25 to $28, according to TradingView citing Benzinga data.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Evercore ISI kept its Outperform rating on Fortrea Holdings and raised the price target to $28 from $25, a 12% increase. According to the report, the new target implies 21% upside from the October 29 close of $23.14, as reported by TradingView, which cites Benzinga data.
The same listing shows recent analyst moves over the past 30 days: UBS kept a Neutral rating with a $24 target, Deutsche Bank upgraded to Buy with a $25 target, and Barclays upgraded to Overweight at $23. Price targets across these three notes range from $23 to $25.
why it matters
Target revisions like this one rarely change the picture on their own, but they show how brokers view a company's outlook. The higher target reflects firmer expectations from Evercore, not a change in reported financials, which the note does not discuss. Investors may treat it as one signal to weigh alongside the company's own results and news.
tags
instruments
sources
- Evercore ISI Group maintains Fortrea Holdings at Outperform, raises price target to $28 from $25 — TradingView, 30 October 2026 at 12:32 UTC
- Evercore ISI Group maintains Kimco Realty at In-Line, raises price target to $25 from $24 — TradingView, 30 October 2026 at 12:38 UTC
- Evercore ISI Group maintains Saia at Outperform, raises price target to $400 from $399 — TradingView, 30 October 2026 at 12:42 UTC
- Evercore ISI Group maintains Quanta Services at Outperform, raises price target to $850 from $800 — TradingView, 30 October 2026 at 12:42 UTC
- Evercore ISI Group maintains Blue Owl Capital at Outperform, raises price target to $12 from $11 — TradingView, 30 October 2026 at 12:41 UTC
- Evercore ISI Group maintains XPO at Outperform, raises price target to $217 from $215 — TradingView, 30 October 2026 at 12:48 UTC
- Evercore ISI Group maintains West Pharmaceutical Servs at Outperform, raises price target to $480 from $440 — TradingView, 30 October 2026 at 12:47 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗